Cirrhosis Clinical Trial
— PREVOCAPOfficial title:
Evaluation of Wireless Capsule Endoscopy for the Detection and the Control of the Esophageal Varices in Children
NCT number | NCT01551966 |
Other study ID # | 2010.644/48 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2011 |
Est. completion date | July 2013 |
Verified date | July 2013 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The portal hypertension (PHT) is the main complication in patients presenting with cirrhosis.
It can be the direct cause of bleeding by rupture of the esophageal or gastric varices and
can also contribute to the development of ascites, hepatic encephalopathy and pleuropulmonary
complications.
In the paediatric population presenting with the PHT, one of every two children develops
varices and thus has a significant risk of bleeding. Safe and easy to use, the video capsule
endoscopy (VCE) is now routinely used in children for the exploration of the small bowel. But
the role of the VCE for examination of the other parts of digestive tract still needs to be
evaluated.
For the esophagus, the VCE could allow the diagnosis without the need of general sedation.
Recent studies have shown a good sensitivity and tolerance of this technique for the initial
diagnosis of esophageal varices (EV) in adult patients presenting with portal hypertension,
but it has not yet been validated for this indication.
The investigators hypothesize that the VCE could be used in children with similar results in
term of efficacy, as for adults.
This prospective simple blind multicentre study (blind for the lecture of the capsule
endoscopy record), will investigate the diagnostic value of the VCE compared to the
conventional esophagogastroduodenoscopy (EGD) under general sedation for the detection and
the control of esophageal varices in children.
If it is provided that the VCE is as efficient as it is for the adults, it could become a
very interesting alternative to the conventional EGD because less expensive and less
invasive. Moreover, this technique would be very useful as a means of early detection on the
EV and/or their control.
Status | Completed |
Enrollment | 100 |
Est. completion date | July 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 18 Years |
Eligibility |
Inclusion Criteria: - patients between 7 and 18 years old - presenting a portal hypertension and/or cirrhosis - patients who are referred for a conventional EGD under general sedation - patients who are not participating in other clinical studies - written informed consent obtained from the patient and his/her legal guardians. Exclusion Criteria: - patients presenting a contra indication for upper endoscopy or for the ingestion of the video capsule, especially those with clinical or radiological suspicion of upper gastrointestinal strictures (esophageal surgery or eosinophile esophagitys) - patients presenting with dysphagia or gastrointestinal tract strictures (patients with Crohn's disease, small bowel carcinoma, stenosis due to the chronic use of a NSAI medication, acute necrotizing enterocolitis or prior abdominal surgery of the gastrointestinal tract); swallowing disorders with or without impaired consciousness; - patients under calcium channel blocking agents medication; - patient presenting with diverticulosis (Marphan's or Ehlers Danlos's syndrome) - patients with cardiac pacemaker or other implanted electro medical device - patients scheduled for a magnetic resonance imaging (MRI) examination within 7 days after ingestion of the capsule (and until the capsule is evacuated) - any other life-threatening conditions. |
Country | Name | City | State |
---|---|---|---|
France | Service de Pédiatrie Médicale, Hôpital Pellegrin, CHU de Bordeaux | Bordeaux | |
France | Service d'Hépatologie, gastroentérologie et nutrition pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon | Bron | |
France | Clinique de Pédiatrie, Hôpital Jeanne de Flandre, CHU de Lille | Lille | |
France | Service de Gastroentérologie, Mucoviscidose et Nutrition, Hôpital Robert Debré, AP-HP | Paris | |
France | Service de Hépato Gastroentérologie et Nutrition, Hôpital Necker Enfants Malades, AP-HP | Paris Cedex 15 | |
France | Service de Pédiatrie, Hôpital Sud, CHU de Rennes | Rennes | |
France | Service de Gastroentérologie, Hépatologie, Nutrition et Diabétologie, Hôpital des Enfants, CHU de Toulouse | Toulouse Cedex 9 |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Cardey J, Le Gall C, Michaud L, Dabadie A, Talbotec C, Bellaiche M, Lamireau T, Mas E, Bridoux-Henno L, Viala J, Restier-Miron L, Lachaux A. Screening of esophageal varices in children using esophageal capsule endoscopy: a multicenter prospective study. E — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic value of the wireless capsule endoscopy | The diagnostic value of the wireless capsule endoscopy as measured by the sensitivity of the wireless capsule endoscopy for the detection and the control of esophageal varices in children compared to the EGD sensitivity. | 1 week | |
Secondary | Diagnostic value comparing the specificity, the positive and negative predictive value (PPV, NPV) of the wireless capsule endoscopy | Diagnostic value comparing the specificity, the positive and negative predictive value (PPV, NPV) of the wireless capsule endoscopy with the results for the EGD under general sedation. | 1 week | |
Secondary | Feasibility and safety of the wireless capsule endoscopy | Feasibility and safety of the wireless capsule endoscopy compared to the conventional EGD under general sedation as expressed by the safe completion of the wireless capsule endoscopy. | 4 weeks | |
Secondary | Acceptance of the wireless capsule endoscopy | Acceptance of the wireless capsule endoscopy by the patient compared to the EGD under general sedation by calculating a comfort score. | 1 week | |
Secondary | Applicability of the wireless capsule endoscopy | Applicability of the wireless capsule endoscopy by evaluating the ability to detect the esophageal or fundic varices, the presence of a portal hypertension gastropathy and the classification of the esophageal varices compared to the EGD results. | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05014594 -
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
|
Phase 2 | |
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT04939350 -
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
|
||
Completed |
NCT02528760 -
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
|
N/A | |
Recruiting |
NCT05484206 -
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
|
Phase 1 | |
Not yet recruiting |
NCT05538546 -
Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Recruiting |
NCT02983968 -
Use of the French Healthcare Insurance Database
|
||
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02596880 -
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
|
Phase 3 | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Completed |
NCT02016196 -
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
|
Phase 3 | |
Withdrawn |
NCT01956864 -
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
|
Phase 1 | |
Completed |
NCT01447537 -
Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis
|
N/A | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01231828 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
|
N/A |